THE FAUCI FILES, Vol 3(16): Antiretroviral Fascist Society's
Recommendations in JAMA
January 19, 2000
Under the tutelage of NIH/NIAID Dictator-Direktor, Dr. Anthony
"Mussolini" Fauci, here's what the "standard of care" defining
group -- the International AIDS Society -- the trend-setter
in AIDS research and treatment -- has become in this orgy
of greed, lies, corruption, murder and hidden pharmaceutical
fascist agendas (their recommendations follow these OUTRAGEOUS
financial conflicts-of-interest disclosures).
Crooked Murdering Bastards!
fred
----
"Updated Recommendations of the International AIDS Society-USA Panel
Charles C. J. Carpenter, MD;
David A. Cooper, MD, DSc;
Margaret A. Fischl, MD;
Jose M. Gatell, MD, PhD;
Brian G. Gazzard, MA, MD;
Scott M. Hammer, MD;
Martin S. Hirsch, MD;
Donna M. Jacobsen, BS;
David A. Katzenstein, MD;
Julio S. G. Montaner, MD;
Douglas D. Richman, MD;
Michael S. Saag, MD;
Mauro Schechter, MD, PhD;
Robert T. Schooley, MD;
Melanie A. Thompson, MD;
Stefano Vella, MD;
Patrick G. Yeni, MD;
Paul A. Volberding, MD
"Financial Disclosures: All authors except Ms Jacobsen
were speakers, advisory board members, and/or consultants,
and/or had stock ownership, research grants, or honoraria
involving 1 or more of the following:
Abbott
Agouron
Biochem Pharma
Boehringer Ingelheim
Bristol-Myers
Squibb
Chiron
DuPont Pharmaceuticals
Gilead Sciences
Glaxo Wellcome
Hoffmann-La Roche
Merck Frosst Laboratories
Merck Sharp & Dohme
Merck
Novirio
Pharmacia & Upjohn
Roche
Roxane
Schering Plough
Triangle
Trimeris
Vertex
ViroLogic
or Visible Genetics.
In the 1/19/2000 JAMA, the International AIDS Society-USA Panel has
updated its recommendations for antiretroviral therapy in adults.
Here's what the collapse of the HAART Cocktail Hoax looks like:
Carpenter et al. (2000) state:
"Offsetting perceived benefits of early treatment of established HIV
infection is growing concern about the long-term adverse effects of
therapy. Apart from adherence problems, impact on quality of life,
drug-drug interactions, and viral resistance, the potential for
metabolic abnormalities raises important long-term concerns,
including possible premature cardiovascular disease."
AND
"Physicians and patients must weigh the risks and benefits of starting
antiretroviral therapy and make individualized informed decisions.
When to initiate therapy and what regimen to choose are crucial
decisions; otherwise, future options may be severely compromised.
Ultimate long-term success may also be a function of the aggregate
effectiveness of sequential therapies."
Full article and references are freely available at
http://jama.ama-assn.org/issues/v283n3/full/jst90023.html
================================
JAMA, January 19, 2000, Volume 283, Pages 381-390
Antiretroviral Therapy in Adults
Updated Recommendations of the International AIDS Society-USA Panel
Charles C. J. Carpenter, MD; David A. Cooper, MD, DSc; Margaret A.
Fischl, MD; Jose M. Gatell, MD, PhD; Brian G. Gazzard, MA, MD; Scott M.
Hammer, MD; Martin S. Hirsch, MD; Donna M. Jacobsen, BS; David A.
Katzenstein, MD; Julio S. G. Montaner, MD; Douglas D. Richman, MD;
Michael S. Saag, MD; Mauro Schechter, MD, PhD; Robert T. Schooley, MD;
Melanie A. Thompson, MD; Stefano Vella, MD; Patrick G. Yeni, MD; Paul A.
Volberding, MD
Abstract: Objective: To update recommendations for antiretroviral
therapy for adult human immunodeficiency virus type 1 (HIV-1) infection,
based on new information and drugs that are available.
Participants: A 17-member international physician panel with
antiretroviral research and HIV patient care experience initially
convened by the International AIDS Society-USA in December 1995.
Evidence: Available clinical and basic science data including phase 3
controlled trials; data on clinical, virologic, and immunologic end
points; research conference reports; HIV pathogenesis data; and panel
expert opinion. Recommendations were limited to therapies available (US
Food and Drug Administration approved) in 1999.
Consensus Process: The panel assesses new research reports and interim
results and regularly meets to consider how the new data affect therapy
recommendations. Recommendations are updated via full-panel consensus.
Guidelines are presented as recommendations if the supporting evidence
warrants routine use in the particular situation and as considerations
if data are preliminary or incomplete but suggestive.
Conclusions: The availability of new antiretroviral drugs has expanded
treatment choices. The importance of adherence, emerging long-term
complications of therapy, recognition and management of antiretroviral
failure, and new monitoring tools are addressed. Optimal care requires
individualized management and ongoing attention to relevant scientific
and clinical information in the field.
Corresponding Author and Reprints: Charles C. J. Carpenter, MD, Brown
University School of Medicine, The Miriam Hospital, 164 Summit Ave,
Providence, RI 02906 (e-mail: Charles_Carpenter at brown.edu).
Financial Disclosures: All authors except Ms Jacobsen were speakers,
advisory board members, and/or consultants, and/or had stock ownership,
research grants, or honoraria involving 1 or more of the following:
Abbott, Agouron, Biochem Pharma, Boehringer Ingelheim, Bristol-Myers
Squibb, Chiron, DuPont Pharmaceuticals, Gilead Sciences, Glaxo Wellcome,
Hoffmann-La Roche, Merck Frosst Laboratories, Merck Sharp & Dohme,
Merck, Novirio, Pharmacia & Upjohn, Roche, Roxane, Schering Plough,
Triangle, Trimeris, Vertex, ViroLogic, or Visible Genetics.
Funding/Support: This work was supported by the International AIDS
Society-USA, San Francisco, Calif.
---
